Compare Invesco NASDAQ 100 ETF (QQQM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco NASDAQ 100 ETF trades at $296.76 (market cap $111.60B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 22.2× Travere Therapeutics Inc. Common Stock's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 56 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QQQM | TVTX | |
|---|---|---|
Market Cap | $111.60B | $5.02B |
Volume | 3,716,107 | 2,060,842 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $67.52 |
52-Week Low | $229.87 | $26.79 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $306.18, down 0.33% with a bullish technical signal from moving averages. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads may offset this benefit. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show neutral oscillators with key support at $304-$306 and resistance at $308-$310.
QQQM offers exposure to Nasdaq-100 growth stocks with competitive fees, but faces competition from alternatives like SCHG and QQQE. The ETF's performance depends on technology sector leadership, with concentration risk in top holdings. Recent news highlights tax implications of similar ETFs, emphasizing the importance of understanding distribution characteristics for long-term returns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
